If conjugated bilirubin is elevated in a patient on a 12-hour cycle of 3-in-1 HPN, which action is most appropriate?

Prepare for the ASPEN Certified Nutrition Support Clinician (CNSC) Exam. Study with structured quizzes and detailed insights to enhance your knowledge and readiness. Get set for success!

Multiple Choice

If conjugated bilirubin is elevated in a patient on a 12-hour cycle of 3-in-1 HPN, which action is most appropriate?

Explanation:
When conjugated bilirubin is elevated in a patient on a 12-hour cycle of 3-in-1 PN, the liver is showing cholestasis related to PN. The most likely cause in this setting is overfeeding from the PN, especially excess dextrose calories or an excessive lipid emulsion. This PN-associated cholestasis tends to improve if the total energy delivered is reduced to match the patient’s actual needs and the lipid dose is titrated appropriately. So the best next step is to evaluate the prescription for possible overfeeding of dextrose and/or intravenous fat emulsion: review the daily carbohydrate and fat amounts, assess whether the energy provided exceeds the patient’s requirements, and adjust the PN accordingly (e.g., lowering dextrose rate or lipid dose, or modifying the cycle). Monitoring liver enzymes and bilirubin over time helps confirm improvement after adjustments. Removing all trace elements isn’t appropriate because they’re essential. Increasing lipid calories would likely worsen the cholestasis, not help it. Adding carnitine and choline can be considered in specific contexts, but they don’t address the immediate issue of PN-associated cholestasis due to overfeeding.

When conjugated bilirubin is elevated in a patient on a 12-hour cycle of 3-in-1 PN, the liver is showing cholestasis related to PN. The most likely cause in this setting is overfeeding from the PN, especially excess dextrose calories or an excessive lipid emulsion. This PN-associated cholestasis tends to improve if the total energy delivered is reduced to match the patient’s actual needs and the lipid dose is titrated appropriately.

So the best next step is to evaluate the prescription for possible overfeeding of dextrose and/or intravenous fat emulsion: review the daily carbohydrate and fat amounts, assess whether the energy provided exceeds the patient’s requirements, and adjust the PN accordingly (e.g., lowering dextrose rate or lipid dose, or modifying the cycle). Monitoring liver enzymes and bilirubin over time helps confirm improvement after adjustments.

Removing all trace elements isn’t appropriate because they’re essential. Increasing lipid calories would likely worsen the cholestasis, not help it. Adding carnitine and choline can be considered in specific contexts, but they don’t address the immediate issue of PN-associated cholestasis due to overfeeding.

Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy